Abstract 865P
Background
The prognosis of early OSCC is strongly correlated with local disease control. However, patients with T1-T2 OSCC and clear margins have a 5-year local relapse rate of around 15%. The evaluation of the quality of surgical resection is therefore essential.
Methods
A prospective multicenter trial based on patients with T1-T2 OSCC treated surgically with clear margins, showed the interest of a molecular analysis (microsatellite instability (MSI)) of surgical margins to evaluate the minimal residual disease (MRD) while adapting the postoperative strategy (NCT00232960). Recently, innovative techniques for detecting circulating tumor DNA have been developed. Our main objective was, then, to evaluate the feasibility of detecting MRD by identifying specific molecular abnormalities with Whole Exom Sequencing (WES) and Shallow Whole Genome Sequencing (ShWGS) in the primary tumor and looking for it on the margins.
Results
310 patients were included initially with 216 tumor/margins samples available for molecular analysis. Tumor was informative for MSI analysis in 63% of cases (n=133). Positive molecular margins were observed in 23 cases, leading to a postoperative treatment. Median follow-up was 58 months [30;83]. In informative tumor, molecularly driven treatment seemed to lower the 5-year local recurrence rate from 14.1% to 6.4% (p=0.15). Among the initial cohort, 108 primary tumors were secondary screened by WES with an informative rate of 78.6%. With a 10X depth for molecular analysis, we observed 13 patients with at least one positive margin. Then, analyzing retrospectively the oncologic outcomes, we observed a significant benefit for local control at 5 years for patients with WES negative margins (91.7% versus 64.1%, p=0.02). We, then, performed a ShWGS analysis on a sub-group of 39 patients. Patients with positive margins both in WES and ShWGS had a higher risk of local relapse at 5 years (p<10-3).
Conclusions
Molecular analysis of surgical margins for early OSCC lead to a better assessment of microscopic residual disease while postoperative decision making according to WES and ShWGS could improve local control.
Clinical trial identification
NCT00232960.
Editorial acknowledgement
Legal entity responsible for the study
GETTEC group (French Group for Study of Head and Neck Tumors).
Funding
PHRC program from INCA (French National Cancer Institute) PRISM program from Gustave Roussy Cancer Campus.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12